TheGridNet
The Vienna Grid Vienna

Vienna
Breaking News

레스토랑 뉴스 기상 레이더 예배-규칙서

주요 기사

Vienna Politics 뉴스

Vienna is establishing a service point in the city hall
Vienna is establishing a service point in the city hall
3 년 전
RTK-Präsident Thomas Ziegler und gesamter Vorstand wiedergewählt
RTK-Präsident Thomas Ziegler und gesamter Vorstand wiedergewählt
3 년 전
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
3 년 전
Austria sees sharp rise in acts of antisemitism
Austria sees sharp rise in acts of antisemitism
3 년 전
Exit poll shows Swiss right-wing party bouncing back in parliamentary election as Greens lose ground
Exit poll shows Swiss right-wing party bouncing back in parliamentary election as Greens lose ground
3 년 전
Exit poll shows Swiss right-wing party bouncing back in parliamentary election as Greens lose ground
Exit poll shows Swiss right-wing party bouncing back in parliamentary election as Greens lose ground
3 년 전
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
3 년 전
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
3 년 전
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
3 년 전
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
3 년 전